Use of interferon-α in patients with West Nile encephalitis: Report of 2 cases

Andre C. Kalil; Marcel P. Devetten; Sanjay Singh; Brandi Lesiak; David P. Poage; Kim Bargenquast; Pierre Fayad; Alison G. Freifeld

doi:10.1086/427945

Use of interferon-α in patients with West Nile encephalitis: Report of 2 cases

Andre C. Kalil, Marcel P. Devetten, Sanjay Singh, Brandi Lesiak, David P. Poage, Kim Bargenquast, Pierre Fayad, Alison G. Freifeld

Research output: Contribution to journal › Article › peer-review

97 Scopus citations

Abstract

We describe 2 patients with West Nile virus (WNV) encephalitis who were treated experimentally with interferon (IFN)-α. Both patients demonstrated substantial improvement in mentation and speech on the second day of experimental therapy, and neither required endotracheal intubation or admission to the intensive care unit during hospitalization. Moreover, during the 9-month follow-up period, one patient achieved complete recovery, and the other nearly achieved complete resolution of sequelae. To our knowledge, this is the first published report of the use of IFN-α to treat WNV encephalitis. Clinical trials are underway to further define the role of this therapy in persons with WNV encephalitis.

Original language	English (US)
Pages (from-to)	764-766
Number of pages	3
Journal	Clinical Infectious Diseases
Volume	40
Issue number	5
DOIs	https://doi.org/10.1086/427945
State	Published - Mar 1 2005

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1086/427945

Cite this

@article{71680a3a719e47cfa29f0c946d9bd064,

title = "Use of interferon-α in patients with West Nile encephalitis: Report of 2 cases",

abstract = "We describe 2 patients with West Nile virus (WNV) encephalitis who were treated experimentally with interferon (IFN)-α. Both patients demonstrated substantial improvement in mentation and speech on the second day of experimental therapy, and neither required endotracheal intubation or admission to the intensive care unit during hospitalization. Moreover, during the 9-month follow-up period, one patient achieved complete recovery, and the other nearly achieved complete resolution of sequelae. To our knowledge, this is the first published report of the use of IFN-α to treat WNV encephalitis. Clinical trials are underway to further define the role of this therapy in persons with WNV encephalitis.",

author = "Kalil, {Andre C.} and Devetten, {Marcel P.} and Sanjay Singh and Brandi Lesiak and Poage, {David P.} and Kim Bargenquast and Pierre Fayad and Freifeld, {Alison G.}",

year = "2005",

month = mar,

day = "1",

doi = "10.1086/427945",

language = "English (US)",

volume = "40",

pages = "764--766",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Use of interferon-α in patients with West Nile encephalitis

T2 - Report of 2 cases

AU - Kalil, Andre C.

AU - Devetten, Marcel P.

AU - Singh, Sanjay

AU - Lesiak, Brandi

AU - Poage, David P.

AU - Bargenquast, Kim

AU - Fayad, Pierre

AU - Freifeld, Alison G.

PY - 2005/3/1

Y1 - 2005/3/1

N2 - We describe 2 patients with West Nile virus (WNV) encephalitis who were treated experimentally with interferon (IFN)-α. Both patients demonstrated substantial improvement in mentation and speech on the second day of experimental therapy, and neither required endotracheal intubation or admission to the intensive care unit during hospitalization. Moreover, during the 9-month follow-up period, one patient achieved complete recovery, and the other nearly achieved complete resolution of sequelae. To our knowledge, this is the first published report of the use of IFN-α to treat WNV encephalitis. Clinical trials are underway to further define the role of this therapy in persons with WNV encephalitis.

AB - We describe 2 patients with West Nile virus (WNV) encephalitis who were treated experimentally with interferon (IFN)-α. Both patients demonstrated substantial improvement in mentation and speech on the second day of experimental therapy, and neither required endotracheal intubation or admission to the intensive care unit during hospitalization. Moreover, during the 9-month follow-up period, one patient achieved complete recovery, and the other nearly achieved complete resolution of sequelae. To our knowledge, this is the first published report of the use of IFN-α to treat WNV encephalitis. Clinical trials are underway to further define the role of this therapy in persons with WNV encephalitis.

UR - http://www.scopus.com/inward/record.url?scp=15044352317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044352317&partnerID=8YFLogxK

U2 - 10.1086/427945

DO - 10.1086/427945

M3 - Article

C2 - 15714427

AN - SCOPUS:15044352317

SN - 1058-4838

VL - 40

SP - 764

EP - 766

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 5

ER -

Use of interferon-α in patients with West Nile encephalitis: Report of 2 cases

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this